Literature DB >> 30343725

Immunopharmacotherapies for Treating Opioid Use Disorder.

Matthew L Banks1, Margaret E Olson2, Kim D Janda3.   

Abstract

The current opioid crisis has reinvigorated interest in the development of therapeutics for opioid use disorder (OUD), and the choice of preclinical translational endpoints is an essential consideration. Antiopioid immunopharmacotherapies (e.g., conjugate vaccines) that sequester drug peripherally, preventing opioids from reaching targeted receptors in the brain, have recently emerged as promising therapeutics.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  choice; drug self-administration; hapten; opioid; vaccine

Mesh：

Substances：

Year:  2018        PMID： 30343725      PMCID： PMC6472257          DOI： 10.1016/j.tips.2018.08.001

Source DB:  PubMed          Journal:  Trends Pharmacol Sci        ISSN： 0165-6147            Impact factor:   14.819


  17 in total

Review 1.  The role of human drug self-administration procedures in the development of medications.

Authors:  S D Comer; J B Ashworth; R W Foltin; C E Johanson; J P Zacny; S L Walsh
Journal:  Drug Alcohol Depend       Date:  2008-04-24       Impact factor: 4.492

2.  Dynamic vaccine blocks relapse to compulsive intake of heroin.

Authors:  Joel E Schlosburg; Leandro F Vendruscolo; Paul T Bremer; Jonathan W Lockner; Carrie L Wade; Ashlee A K Nunes; G Neil Stowe; Scott Edwards; Kim D Janda; George F Koob
Journal:  Proc Natl Acad Sci U S A       Date:  2013-05-06       Impact factor: 11.205

3.  Combatting Synthetic Designer Opioids: A Conjugate Vaccine Ablates Lethal Doses of Fentanyl Class Drugs.

Authors:  Paul T Bremer; Atsushi Kimishima; Joel E Schlosburg; Bin Zhou; Karen C Collins; Kim D Janda
Journal:  Angew Chem Int Ed Engl       Date:  2016-02-16       Impact factor: 15.336

4.  Vaccine for cocaine dependence: a randomized double-blind placebo-controlled efficacy trial.

Authors:  Thomas R Kosten; Coreen B Domingo; Daryl Shorter; Frank Orson; Charles Green; Eugene Somoza; Rachelle Sekerka; Frances R Levin; John J Mariani; Maxine Stitzer; D Andrew Tompkins; John Rotrosen; Vatsal Thakkar; Benjamin Smoak; Kyle Kampman
Journal:  Drug Alcohol Depend       Date:  2014-04-16       Impact factor: 4.492

Review 5.  Insights from Preclinical Choice Models on Treating Drug Addiction.

Authors:  Matthew L Banks; S Stevens Negus
Journal:  Trends Pharmacol Sci       Date:  2016-12-02       Impact factor: 14.819

6.  Effects of buspirone and the dopamine D3 receptor compound PG619 on cocaine and methamphetamine self-administration in rhesus monkeys using a food-drug choice paradigm.

Authors:  William S John; Ashwini K Banala; Amy H Newman; Michael A Nader
Journal:  Psychopharmacology (Berl)       Date:  2014-10-21       Impact factor: 4.530

7.  Effects of chronic buspirone treatment on cocaine self-administration.

Authors:  Nancy K Mello; Peter A Fivel; Stephen J Kohut; Jack Bergman
Journal:  Neuropsychopharmacology       Date:  2012-10-17       Impact factor: 7.853

8.  Multisite, randomized, double-blind, placebo-controlled pilot clinical trial to evaluate the efficacy of buspirone as a relapse-prevention treatment for cocaine dependence.

Authors:  Theresa M Winhusen; Frankie Kropp; Robert Lindblad; Antoine Douaihy; Louise Haynes; Candace Hodgkins; Karen Chartier; Kyle M Kampman; Gaurav Sharma; Daniel F Lewis; Paul VanVeldhuisen; Jeff Theobald; Jeanine May; Gregory S Brigham
Journal:  J Clin Psychiatry       Date:  2014-07       Impact factor: 4.384

9.  Buspirone reduces sexual risk-taking intent but not cocaine self-administration.

Authors:  B Levi Bolin; Joshua A Lile; Katherine R Marks; Joshua S Beckmann; Craig R Rush; William W Stoops
Journal:  Exp Clin Psychopharmacol       Date:  2016-06       Impact factor: 3.157

10.  Pharmacokinetic correlates of the effects of a heroin vaccine on heroin self-administration in rats.

Authors:  Michael D Raleigh; Paul R Pentel; Mark G LeSage
Journal:  PLoS One       Date:  2014-12-23       Impact factor: 3.240
View more
  7 in total

1.  Vaccine blunts fentanyl potency in male rhesus monkeys.

Authors:  Rebekah D Tenney; Steven Blake; Paul T Bremer; Bin Zhou; Candy S Hwang; Justin L Poklis; Kim D Janda; Matthew L Banks
Journal:  Neuropharmacology       Date:  2019-07-29       Impact factor: 5.250

2.  Effectiveness and selectivity of a heroin conjugate vaccine to attenuate heroin, 6-acetylmorphine, and morphine antinociception in rats: Comparison with naltrexone.

Authors:  Kathryn L Schwienteck; Steven Blake; Paul T Bremer; Justin L Poklis; E Andrew Townsend; S Stevens Negus; Matthew L Banks
Journal:  Drug Alcohol Depend       Date:  2019-08-24       Impact factor: 4.492

Review 3.  Unique Pharmacology, Brain Dysfunction, and Therapeutic Advancements for Fentanyl Misuse and Abuse.

Authors:  Ying Han; Lu Cao; Kai Yuan; Jie Shi; Wei Yan; Lin Lu
Journal:  Neurosci Bull       Date:  2022-05-15       Impact factor: 5.271

Review 4.  Medications Development for Treatment of Opioid Use Disorder.

Authors:  E Andrew Townsend; S Stevens Negus; Matthew L Banks
Journal:  Cold Spring Harb Perspect Med       Date:  2021-01-04       Impact factor: 6.915

5.  Acceptability of a Fentanyl Vaccine to Prevent Opioid Overdose and Need for Personalized Decision-Making.

Authors:  Elissa R Weitzman; Joe Kossowsky; Laura M Blakemore; Rachele Cox; David J Dowling; Ofer Levy; Emma W Needles; Sharon Levy
Journal:  Clin Infect Dis       Date:  2022-08-15       Impact factor: 20.999

6.  Effects of exogenous ghrelin administration and ghrelin receptor blockade, in combination with alcohol, on peripheral inflammatory markers in heavy-drinking individuals: Results from two human laboratory studies.

Authors:  Mehdi Farokhnia; Jeanelle Portelli; Mary R Lee; Gray R McDiarmid; Vikas Munjal; Kelly M Abshire; Jillian T Battista; Brittney D Browning; Sara L Deschaine; Fatemeh Akhlaghi; Lorenzo Leggio
Journal:  Brain Res       Date:  2020-04-24       Impact factor: 3.252

Review 7.  Preclinical Evaluation of Vaccines to Treat Opioid Use Disorders: How Close are We to a Clinically Viable Therapeutic?

Authors:  E Andrew Townsend; Matthew L Banks
Journal:  CNS Drugs       Date:  2020-05       Impact factor: 5.749
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.